Cytotoxicity, cellular uptake and DNA damage by daunorubicin and its new analogues with modified daunosamine moiety

Cell Biology and Toxicology

Volumn 21, Issue 3-4, 2005, Pages 139-147

  Ciesielska, E ^a   Studzian, K ^a   Wasowska M ^b   Oszczapowicz, I ^b   Szmigiero, L ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b INDUSTRIAL CHEMISTRY RESEARCH INSTITUTE   (Poland)

Author keywords

Anthracyclines; Cellular uptake; Cytotoxicity; DNA damage

Indexed keywords

2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; DAUNORUBICIN DERIVATIVE; DAUNOSAMINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DRUG METABOLITE; HEXAMETHYLENEIMINE DERIVATIVE; MORPHOLINE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELLULAR DISTRIBUTION; COVALENT BOND; CROSS LINKING; CYTOTOXICITY; DNA ADDUCT; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; DRUG UPTAKE; ENZYME INHIBITION; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA INTERACTION;

ANIMALIA;

EID: 27944443628     PISSN: 07422091     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10565-005-0142-1     Document Type: Article

References (24)

1. Andoh T, Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochim Biophys Acta. 1998;1400:155-71.
2. Binaschi M, Farinosi R, Austin CA, Fisher LM, Zunino F, Capranico G. Human DNA topoisomerase II alpha-dependent DNA cleavage and yeast cell killing by anthracycline analogues. Cancer Res 1998;58:1886-92.
3. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of tetrazolium-based semiautomatic colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987;47:936-42.
4. Cullinane C, Cutts SM, Panousis C, Philips DR. Interstrand crosslinking by adriamycin in nuclear and mitochondrial DNA of MCF-7 cells. Nucleic Acids Res. 2000;28:1019-25.
5. Fornace AJ, Dobson PP, Kinsella TJ. Analysis of the effect of DNA alkylation on alkaline elution. Carcinogenesis. 1986;7:927-32.
6. Guano F, Pourquier P, Tinelli S, et al. Topoisomerase poisoning activity of novel disaccharide anthracyclines. Mol Pharmacol. 2001;56:77-84.
7. Jensen LH, Dejligbjerg M, Hansen LT, Grauslund M, Jensen PB, Sehested M. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells. BMC Pharmacol. 2004;4:31.
8. Kohn KW. Principles and practice of DNA filter elution Pharmacol Ther. 1991;49:55-77.
9. Lotfi K, Zackrisson A-L, Peterson C. Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis and resistance. Cancer Letters. 2002;178:141-9.
10. Madej J, Dzimira S, Wsowska M, et al. New derivatives of anthracycline antibiotics with lower cardiotoxicity. First ISC International Conference on Cancer Therapeutics Molecular Targets, Pharmacology and Clinical Applications. J Chemother. 2004;16(supplement 1):154.
11. Monneret C. Recent developments in the field of antitumor anthracyclines. Eur J Med Chem. 2001;36:483-93.
12. Opolski A, Wsowska M, Wietrzyk J, Nasulewicz A, Oszczapowicz I, Oszczapowicz J. Properties of the new anthracycline derivatives, containing modified daunosamine moiety. Symposium on Molecular Targets and Cancer Therapeutics. Frankfurt 19-22 November 2002. Eur J Cancer. 2002;38(supplement 7):47.
13. Oszczapowicz I, Grodner J, Glazman-Kuśnierczyk H, Radzikowski C, Opolski A. Polish Patent Application No. 321175; 1997.
14. Patel S, Jazrawi E, Creighton AM, Austin CA, Fisher LM. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase II. Mol Pharmacol. 2000;58:560-8.
15. Pawłowska J, Tarasiuk J, Borowski E, Wa̧sowska M, Oszczapowicz I, Wolf CR. The ability of new formamidine sugar-modified derivatives of daunorubicine to stimulate free radical formation in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase and xanthine oxidase. Acta Biochim Pol. 2000;47:141-47.
16. Piestrzeniewicz MK, Wilmanska D, Szmraj J, Studzian K, Gniazdowski M. Interactions of novel morpholine and hexamethylene derivatives of anthracycline antibiotics with DNA. Z Naturforsch. 2004;59c:739-48.
17. Riganti C, Miraglia E, Viarisio D, et al. Nitric oxide reverts the resistance to doxombicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res. 2005;65:516-25.
18. Sehested M, Jensen PB, Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclambicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol. 1996;51:879-86.
19. Sessa C, Zucchetti M, Ghelmini M, et al. Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243). Cancer Chemother Pharmacol. 1999;44:403-10.
20. Strniste GF, Rall SC. Induction of stable protein deoxyribonucleic acid adducts in Chinese hamster cell chromatin by ultraviolet light. Biochemistry. 1976;15:1712-9.
21. Studzian K, Wasowska M, Piestrzeniewicz MK, et al. Inhibition of RNA synthesis in vitro and cell growth by anthracycline antibiotics. Neoplasma. 2001;48:412-8.
22. Taatjes DJ, Fenick DJ, Gaudiano G, Koch TH. A redox pathway leading to the alkylation of nucleic acids by doxorubicin and related anthracyclines, application to the design of antitumor drugs for resistant cancer. Curr Pharm Des. 1998;.4:203-18.
23. Walicka M, Szmigiero L, Ciesielska E, Gradzka I. Are lethal effects of nitracrine on L5178Y cell sublines associated with DNA-protein cross-links? Biochem Pharmacol. 1993;46:615-20.
24. Wasserman K, Markovits J, Jaxel C, Capranicao G, Kohn KW, Pommier Y. Effects morpholinyl doxorubicins, daunorubicins, and actinomycin D on mammalin DNA topoisomerase I and II. Mol Pharmacol. 1990;38:38-15.